Blood glucose control and microvascular and macrovascular complications in diabetes

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Hanssen, Kristian F ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0030930204     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s101     Document Type: Conference Paper

References (28)

1. Hanssen KF, Bangstad H-J, Brinchmann-Hansen O, Dahl-Jørgensen K: Blood glucose control and diabetic microvascular complications: long term effects of near-normoglycemia. Diabetic Med 9:697-705, 1992
2. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood glucose control on late complications of type 1 diabetes. Lancet 341:1306-1309, 1993
3. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
5. DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720, 1995
6. Krolewski AS, Laffel LMB, Krolewski M, Quinn M: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-1255, 1995
7. Reichard P: Are there any glycemic thresholds for the serious microvascular diabetic complications? J Diabetes Complications 9:25-30, 1995
8. DCCT Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
9. Brinchmann-Hansen O, Dahl-Jørgensen K, Sandvik L, Haussen KF: Blood glucose concentration and progression of diabetic retinopathy: the seven year results of the Oslo Study. Br Med J 304:19-22, 1992
10. DCCT Research Group: The effect of intensive treatment of diabetes on progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 113:36-51, 1995
11. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J: Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 19:313-317, 1996
12. Colwell JA: DCCT findings: applicability and implications for NIDDM. Diabetes Rev 2:277-291, 1994
13. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: Relationship of hyperglycemia to the long term incidence and progression of diabetic retinopathy. Arch Intern Med 154:2169-2178, 1994
14. Moss SE, Klein R, Klein BEK, Meuer SM: The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473-2479, 1994
15. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:2.58-268, 1995
16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
17. Santiago JV: Lessons from the Diabetes Control and Complications Trial. Diabetes 42:1549-1554, 1993
18. Borch-Johnsen K, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Parving H-H: Is diabetic nephropathy an inherited complication? Kidney Int 41:719-722, 1992
19. Kuusisto J, Mykkänen L, Pyörölä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
20. Andersson DKG, Svärdsudd K: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
21. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, Nuttal F, Sawin C, the VA Cooperative Study Group (CSDM): Glycemic control and complications in type II diabetes: design of a feasibility trial. Diabetes Care 15:1560-1571, 1992
22. Abraira C, Colwell JA, Nuttall FQ, the VACSDM group: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Diabetes Care 18:1113-1123, 1995
23. Turner R, Cull C, Holamn R, UKPDS17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in NIDDM. Ann Intern Med 124:136-145, 1996
24. Birkeland KI, Rishaug U, Vaaler S, Hanssen KF: NIDDM: a rapid progressive disease. Diabetologia 39:1629-1633, 1996
25. Vlassara H, Bucala R: Advanced glycation endproducts (AGE) and diabetes complications: an update. In Diabetes Annual. Vol. 9. Home P, Marshall S, Eds. Amsterdam, Elsevier, 1995, p. 227-244
26. Berg TJ, Torjesen PA, Bangstad H-J, Bucala R, Østerby R, Hanssen KF: Advanced glycation endproducts (AGE) predict changes in kidney morphology of IDDM patients. Metabolism 46:661-665, 1997
27. Dahl-Jørgensen K, Brinchmann-Hansen O, Bangstad H-J, Hanssen KF: Blood glucose control and microvascular complications: what do we do now? Diabetologia 37:1172-1177, 1994
28. American Diabetes Association: Consensus statement the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 18:1510-1518, 1995